EUCTR2015-004601-17-ES进行中（未招募）1 期
A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
European Organisation For Research and Treatment of Cancer (EORTC)0 个研究点目标入组 160 人开始时间: 2017年4月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •?Recurrent, histologically proven, platinum-resistant, epithelial ovarian cancer, fallopian tube and primary peritoneal cancer in advanced or metastatic stage. Histological diagnosis by image guided biopsy, laparoscopy or laparotomy. Tumors diagnosed on cytology only and borderline tumors (i.e. low malignant potential) are excluded
- •?At least one lesion accessible to biopsy without putting patient at risk
- •?Prior systemic (chemotherapy, hormonal therapy, biologic agents, and/or vaccines) or radiation treatment:
- •*Systemic anti-tumoral treatment: wash-out period of 21 days prior to the first study treatment
- •*Any number of platinum-based chemotherapy lines are allowed but a maximum of 2 previous non-platinum containing lines
- •*Prior treatment with bevacizumab or other targeted agents against VEGF or VEGF receptor is allowed, but at least 18 weeks must have elapsed since their last administration
- •*Eligible patients with = 2 previous treatment lines must have been previously exposed to bevacizumab or other targeted agents against VEGF or VEGF receptor
- •*Recovery from any toxic effects of prior therapy to = Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0) except fatigue or alopecia.
- •*Radiation therapy: recovery period of 14 days prior to the first study treatment; exception: single fraction radiotherapy with the indication of pain control and no prior radiation to the pelvis
- •?Age =18 years
- •?WHO PS: 0-2 for patients having received no more than two previous lines of therapy. WHO PS: 0-1 for patients having received >2 previous lines of therapy
- •?Life expectancy of = 12 weeks
- •?Adequate hematologic and end organ function, defined by laboratory results (see protocol at section 3.1 for details) obtained within 14 days prior to randomization
- •?Patients with past/resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. HBV DNA must be obtained in patients with positive hepatitis B core antibody prior to randomization
- •?Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
- •?Women of childbearing potential (WOCP: defined as a sexually mature woman who 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally post-menopausal (amenorrhoea following cancer therapy does not rule out childbearing potential) for at least 12 consecutive months (i.e. has had menses at any time in the preceding 12 consecutive months)) must:
- •Have a negative serum pregnancy test within 7 days prior to randomization.
- •Agree to remain sexually abstinent, have a partner who is sterile (i.e., vasectomy), or use two medically effective methods of contraception during dosing and through 6 months after last study treatment. An effective method is the combination of the following (a+b): a. Hormonal method eg, birth control pills; b. Placement of an intrauterine device (IUD) or intrauterine system (fUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/ gel/film/ cream/vaginal suppository. This requirement should be followed from screening through 24 weeks after last study treatment.
- •During treatment: Patient should agree to urine pregnancy test to be performed before each treatment;
- •Agree to discontinue treatment in case of pregnancy or positive pregnancy test.
- •?Before patient registration/randomization,
排除标准
- •-current, recent (within 4 weeks of randomization}, or planned
- •participation in an experimental drug study
- •-uncontrolled hypercalcemia [>1.5 mmoi/L (4.8 mg/dl) ionized
- •calcium, or Total Ca>3 mmoi/L (12 mg/dl) or corrected serum calcium
- •>ULN] or symptomatic hypercalcemia requiring continued use of
- •bisphosphonate therapy or denosumab
- •-symptomatic brain or leptomeningeal disease; any brain metastases
- •not stable for at least 6 months
- •-presence of uncontrolled pleural effusion, pericardial effusion, or
- •ascites requiring recurrent drainage procedures (once monthly or more frequently)
- •-significant cardiovascular disease, such as:
- •*inadequately controlled hypertension (defined as systolic blood
- •pressure>150 mm Hg and/or diastolic blood pressure>100 mm Hg
- •despite intensive medical management} or prior history of hypertensive crisis or hypertensive encephalopathy. Anti-hypertensive therapy is allowed.
- •*New York Heart Association Class II or greater congestive heart failure and history of myocardial infarction or unstable angina within 6 months prior to randomization (Appendix D)
- •*significant vascular disease including stroke, transient ischemic attack, aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis within 6 months prior to randomization
- •-evidence of bleeding diathesis or significant coagulopathy (in the
- •absence of therapeutic anticoagulation) and current or recent (within 10 days prior to randomization} use of dipyridamole, ticlopidine,
- •clopidogrel, cilostazol, prasugrel, or ticagrelor; or use of full dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic} purpose
- •-obvious signs of, or risks for gastrointestinal fistula formation or
- •perforation, such as:
- •*History of abdominal or tracheoesophageal fistula or gastrointestinal
- •perforation within 6 months prior to randomization
- •*clinical signs or symptoms of gastrointestinal obstruction or
- •requirement for routine parenteral hydration, parenteral nutrition, or
- •tube feeding
- •-serious, non-healing or dehiscing wound, active ulcer, or untreated
- •bone fracture. Surgery (including open but not core biopsy} within 4
- •weeks prior to randomization, or anticipation of the need for major
- •surgery during study treatment
- •-proteinuria, as demonstrated by urine dipstick >1+ or> 1 .0 g of
- •protein in a 24-hour urine collection (All patients with > or = 2+ protein on dipstick urinalysis at baseline must undergo a 24 hour urine
- •collection for protein and will remain eligible if < 1.0 g of protein
- •detected} within 2 weeks of randomization
- •-history of inflammatory bowel disease or any autoimmune disease,
- •including but not limited to myasthenia gravis, myositis, autoimmune
- •hepatitis, systemic lupus erythematosus, rheumatoid arthritis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, type I diabetes mellitus, vasculitis, or glomerulonephritis
- •-history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,
- •bronchiolitis obliterans}, drug-induced pneumonitis, idiopathic
- •pneumonitis, or evidence of active pneumonitis on screening chest CT
- •-positivity for infections:
- •*signs or symptoms of infection or therapeutic use of antibiotics (except prophylactic antibiotics} within 2 weeks prior to randomization and severe infections within 4 weeks prior to randomization, including but
- •not limited to hospitalization for complications of in
研究者
相似试验
已完成
2 期
A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinomaNL-OMON50342Radboud Universitair Medisch Centrum38
进行中（未招募）
1 期
Immunotherapy, bevacizumab and ASA in recurrent ovarian cancerOvarian neoplasmsMedDRA version: 20.0Level: LLTClassification code 10051938Term: Ovarian adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004601-17-GBEuropean Organisation For Research and Treatment of Cancer (EORTC)96
进行中（未招募）
1 期
Immunotherapy, bevacizumab and ASA in recurrent ovarian cancerOvarian neoplasmsMedDRA version: 20.0Level: LLTClassification code 10051938Term: Ovarian adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004601-17-NLEuropean Organisation For Research and Treatment of Cancer (EORTC)96
进行中（未招募）
1 期
Immunotherapy, bevacizumab and ASA in recurrent ovarian cancerOvarian neoplasmsMedDRA version: 19.1Level: LLTClassification code 10051938Term: Ovarian adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004601-17-FREuropean Organisation For Research and Treatment of Cancer (EORTC)160
已完成
2 期
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian CancerOvarian NeoplasmsNCT02659384European Organisation for Research and Treatment of Cancer - EORTC122